



**Research Consensus Panel for the Development of a Research Agenda in
 Management of Metastatic Colorectal Cancer**

Monday, October 3, 2011

Hyatt Dulles

Conference Room: Cirrus A&B

2300 Dulles Corner Blvd.,

Herndon, Virginia, USA 20171

8:30am – 3:00pm

(8:00-8:30 a.m. Continental Breakfast)

Meeting Agenda

OBJECTIVE: To define a prioritized research agenda for the management of metastatic colorectal cancer, including topics amenable to basic science/technology research, pilot clinical research, and multi-center clinical trials. This process will involve several steps:

1. **PANELISTS' RESEARCH PRESENTATIONS AND DISCUSSION:** Key aspects of the already-existing knowledge base for each research domain will be summarized by a panel member. A moderated discussion will be held to address the following questions for each domain:

1. What are the most important clinical questions that could realistically be answered now through pivotal multi-institutional clinical trials or registries?
2. What are the most promising future directions that merit pre-clinical or early clinical exploration in management of metastatic colorectal cancer?
3. What critical alliances must be developed to advance the prioritized research, and how can SIR Foundation best support these initiatives?

2. **PRIORITIZATION:** Based upon the discussion, a summary list of potential research studies will be created. The panelists will rank the research projects in order of priority. The results will be compiled into a final rank list.

3. **PROTOCOL DEVELOPMENT:** The top-ranked research priority will be examined by the panel. A basic framework research protocol designed to address this question will be developed, with a strong focus on determining how to study the outcomes that are clinically meaningful.

Time Slot	Topic	Speaker
8:30-8:55 a.m.	Introductions. Explanation of the RCP Proceedings followed by the Lead Investigator's presentations: Current trials on available IR treatments for metastatic CRC	Dr. Stephen Kee, Moderator/ Dr. Bertrand Janne d'Othee, RCP Lead Investigator
8:55-9:05 a.m.	Panelist 1: Liver Metastases from CRC: Natural History and Current NCCN Guidelines	Dr. Alan Venook, Medical Oncologist
9:05-9:15 a.m.	Panelist 2: Surgical Outcomes of Colorectal Cancer (CRC) Hepatic Metastatectomy	Dr. Nader Hanna, Surgical Oncologist
9:15-9:25 a.m.	Panelist 3: Surgery for Liver Metastases of CRC: Resection (2-Stage vs. 1-Stage +/-	Dr. Jean-Nicolas Vauthey, Surgical Oncologist

	Portal Vein Ligation) +/- Intraoperative RFA	
9:25-9:45 a.m.	Panelist 4: 1. Outcomes of Percutaneous Ablative Therapies (RFA & others) for Liver Metastases of CRC 2. Role of Intra-arterial Hepatic Chemotherapy	Dr. Costantinos Sofocleous, IR
9:45-9:55a.m.	Panelist 5: Review of Chemotherapy with Radioembolization.	Dr. Steven Cohen, Medical Oncologist
9:55-10:05a.m.	Panelist 6: The First of Two Presentations on: Outcomes of Chemoembolization of Liver Metastases of CRC	Dr. Michael Soulen, IR
10:05-10:15 a.m.	Panelist 7: The Second of Two Presentations on: Outcomes of Chemoembolization of Liver Metastases of CRC	Dr. Jean-Francois Geschwind, IR
10:15-10:25 a.m.	Panelist 8: The First of Two Presentations on: Outcomes of Radioembolization of Liver Metastases of CRC	Dr. Matthew Johnson, IR
10:25-10:35 a.m.	Panelist 9: The Second of Two Presentations on: Outcomes of Radioembolization of Liver Metastases of CRC	Dr. Robert Lewandowski, IR
10:35-10:45 a.m.	Panelist 10: Outcomes of External Radiation Therapy of Liver Metastases of CRC	Dr. Andrew Kennedy, Radiation Oncologist
10:45- 10:55 a.m.	Panelist 11: Portal Vein Embolization & Role of Y90 Microspheres	Dr. Ravi Murthy, IR
10:55-11:05 a.m.	BREAK (10 minutes)	All
11:05 a.m.-12:00 noon	<p>Panel Discussion & Research Priority Topic Suggestions. (Priorities are typed for viewing on the screen and numbered as they are stated.)</p> <ul style="list-style-type: none"> ➤ TWO rounds around the panel table. <ul style="list-style-type: none"> 1. Round 1- Brainstorming. Panel discussion. Each panelist has the opportunity to address the questions listed on page one of the agenda under Panel Discussion. 2. Round 2- Each panelist suggests 1 or 2 clinical priorities and 1 basic science priority (optional: 1 organizational priority) ➤ Audience participants have the opportunity to suggest research priority topics (1 or 2 clinical, 1 basic science and 1 organizational). 	<p>Panel</p> <p>Audience</p>

12:00-12:20 p.m.	Panel reviews the listed priorities and makes an effort to further consolidate/combine priorities into a list of 10 to 15 priorities. Panel agrees to any combinations that are made.	Panel
12:20-12:30 p.m.	Panelists vote on the priority topics.	Panel
12:30-1:15 p.m.	Lunch (Voting sheets are collected from panelists, votes are tallied.)	Dr. Bertrand Janne d'Othee/Staff tally votes
1:15-1:30 p.m.	Voting results are announced and the 1 or 2 top clinical priority research topics are identified	Dr. Bertrand Janne d'Othee
1:30-2:30 p.m.	<ul style="list-style-type: none"> ➤ Panel will suggest which panelist(s) will apply for the Funding Source Development Grant (Dec. 14th deadline), which funds the development of a protocol for a clinical research trial on one of the top RCP priorities. ➤ For the priority topic(s) : <ul style="list-style-type: none"> ▪ The protocol development is discussed as time allows answering questions such as: <ol style="list-style-type: none"> 1. What is the public health significance of the study? 2. What would be the study's primary and secondary aims? 3. What would be the study design? 4. What would be the primary and secondary outcome measures? 5. What would be the inclusion, exclusion criteria for participation in the study? What would be the study's structure? 	<p>Dr. Bertrand Janne d'Othee facilitates the discussion with the panelists, the audience may contribute.</p> <ul style="list-style-type: none"> ➤ For more information on the Funding Source Development Grant application go to : <ol style="list-style-type: none"> 1. http://www.sirfoundation.org/grants-awards 2. And/or contact kmercure@sirweb.org
2:30-3:00 p.m.	Summary and meeting conclusion	Dr. Bertrand Janne d'Othee/Dr. Stephen Kee